Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Given Average Rating of "Hold" by Brokerages
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Given Average Rating of "Hold" by Brokerages
Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) has received an average rating of "Hold" from the twelve brokerages that are covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $78.22.
Marketbeat報道,Turning Point Therapeutics, Inc.(納斯達克股票代碼:TPTX — 獲取評級)已獲得報道該股的十二家經紀公司的平均評級 “持有”。八位研究分析師對該股進行了持有評級,三位對該公司給出了買入評級。去年發佈該股報告的分析師的平均12個月股價目標爲78.22美元。
Several research firms have recently commented on TPTX. SVB Leerink lowered Turning Point Therapeutics from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $101.00 to $76.00 in a research note on Monday, June 13th. Guggenheim set a $76.00 target price on shares of Turning Point Therapeutics in a report on Monday, June 20th. Cowen downgraded shares of Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, June 6th. Wells Fargo & Company downgraded shares of Turning Point Therapeutics from an "overweight" rating to an "equal weight" rating and set a $76.00 target price for the company. in a report on Friday, June 3rd. Finally, Cowen downgraded shares of Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, June 6th.
幾家研究公司最近對TPTX發表了評論。SVB Leerink在6月13日星期一的一份研究報告中將Turning Point Therapeutics從 “跑贏大盤” 的評級下調至 “市場表現”,並將該股的目標股價從101.00美元下調至76.00美元。古根海姆在6月20日星期一的一份報告中爲Turning Point Therapeutics的股票設定了76.00美元的目標價格。Cowen在6月6日星期一的一份報告中將Turning Point Therapeutics的股票評級從 “跑贏大盤” 下調至 “市場表現”。富國銀行在6月3日星期五的一份報告中將Turning Point Therapeutics的股票評級從 “增持” 下調至 “同等權重”,併爲該公司設定了76.00美元的目標價格。最後,Cowen在6月6日星期一的一份報告中將Turning Point Therapeutics的股票評級從 “跑贏大盤” 下調至 “市場表現”。
Insider Buying and Selling at Turning Point Therapeutics
Turning Point Therapeutics 的
In other Turning Point Therapeutics news, CFO Paolo Tombesi sold 1,183 shares of the stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $74.94, for a total transaction of $88,654.02. Following the completion of the transaction, the chief financial officer now owns 28,700 shares of the company's stock, valued at approximately $2,150,778. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 8.60% of the company's stock.
在Turning Point Therapeutics的其他新聞中,首席財務官保羅·湯貝西在7月27日星期三的交易中出售了該股1,183股。這些股票的平均售價爲74.94美元,總交易額爲88,654.02美元。交易完成後,首席財務官現在擁有該公司28,700股股票,價值約2,150,778美元。該交易已在向美國證券交易委員會提交的法律文件中披露,該文件可通過美國證券交易委員會網站訪問。內部人士擁有該公司8.60%的股票。
Institutional Inflows and Outflows
機構流入和流出
Turning Point Therapeutics Trading Up 0.7 %
Turning Point Therapeutic
Shares of TPTX opened at $76.01 on Monday. The firm has a market cap of $3.81 billion, a PE ratio of -11.02 and a beta of -0.18. Turning Point Therapeutics has a 1-year low of $23.77 and a 1-year high of $82.20. The firm has a fifty day simple moving average of $75.49 and a two-hundred day simple moving average of $54.27.
週一,TPTX的股價開盤價爲76.01美元。該公司的市值爲38.1億美元,市盈率爲-11.02,beta值爲-0.18。Turning Point Therapeutics的1年低點爲23.77美元,爲1年高點82.20美元。該公司的五十天簡單移動平均線爲75.49美元,兩百天簡單移動平均線爲54.27美元。
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The company reported ($2.48) EPS for the quarter, missing the consensus estimate of ($1.78) by ($0.70). The firm had revenue of $0.12 million during the quarter, compared to analysts' expectations of $2.27 million. Turning Point Therapeutics's quarterly revenue was down 97.7% compared to the same quarter last year. During the same period last year, the business earned ($1.14) EPS. As a group, research analysts forecast that Turning Point Therapeutics will post -7.69 EPS for the current fiscal year.
Turning Point Therapeutics(納斯達克股票代碼:TPTX — 獲取評級)最後一次公佈其季度收益數據是在8月8日星期一。該公司公佈的本季度每股收益(2.48美元),比市場普遍預期的(1.78美元)低了(0.70美元)。該公司在本季度的收入爲12萬美元,而分析師的預期爲227萬美元。Turning Point Therapeutics的季度收入與去年同期相比下降了97.7%。去年同期,該公司的每股收益爲(1.14美元)。總體而言,研究分析師預測,Turning Point Therapeutics將在本財年公佈每股收益-7.69美元。
Turning Point Therapeutics Company Profile
轉折點療法公司簡介
(Get Rating)
(獲取評級)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point Therapeutics, Inc是一家臨床階段的精準腫瘤生物製藥公司,致力於設計和開發針對癌症遺傳驅動因素的療法。它開發了一系列酪氨酸激酶抑制劑 (TKI),用於靶向 TKI-naive 和 TKI 預治療患者的癌症遺傳驅動因素。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 免費獲取 StockNews.com 關於 Turning Point Therapeutics(TPTX)的研究報告的副本
- Kroger's 是您的一站式必需消費品股票
- Adobe 爲投資者完善了 Faceplant 的藝術
- 稅收抵免是《減少通貨膨脹法》中的激勵措施
- 第四季度值得考慮的3家銀行
- 股市:紅海中的三個力量之島
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收每日轉折點治療的新聞和收視率 -在下面輸入您的電子郵件地址,通過Marketbeat.com的免費每日電子郵件時事通訊接收Turning Point Therapeutics及相關公司最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。